Etanercept in severe active rheumatoid arthritis: first Australian experience

Background: Etanercept reduces disease activity in adults with chronic rheumatoid arthritis (RA) who are resistant to other therapies. Medicare Australia Pharmaceutical Benefit Scheme subsidized treatment (since August 2003) restricts etanercept availability to a most drug‐resistant RA population. T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal medicine journal 2006-10, Vol.36 (10), p.625-631
Hauptverfasser:	Perera, L. C., Tymms, K. E., Wilson, B. J., Shadbolt, B., Brook, A. S., Dorai Raj, A. K., Khoo, K. B. K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antirheumatic Agents - pharmacology Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - epidemiology Australia Australia - epidemiology Biological and medical sciences Diseases of the osteoarticular system Etanercept Female General aspects Humans Immunoglobulin G - pharmacology Immunoglobulin G - therapeutic use Inflammatory joint diseases Male Medical sciences Middle Aged Pain Measurement - drug effects Prospective Studies Receptors, Tumor Necrosis Factor - therapeutic use rheumatoid arthritis Severity of Illness Index treatment tumour necrosis factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!